Atripla (HIV) - Forecast and Market Analysis to 2022

NEW YORK, April 16, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Atripla (HIV) - Forecast and Market Analysis to 2022

http://www.reportlinker.com/p01158427/Atripla-HIV---Forecast-and-Market-Analysis-to-2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

Atripla (HIV) - Forecast and Market Analysis to 2022

Summary

GlobalData has released its new PharmaPoint Drug Evaluation report, "Atripla (HIV) - Forecast and Market Analysis to 2022". Human Immunodeficiency Virus (HIV), the causative agent of AIDS, has claimed millions of lives since its emergence. However, the advent of antiretroviral therapy (ART) has transformed the face of HIV/AIDS from a deadly disease to a manageable chronic condition for most infected individuals. Antiretroviral treatment not only reduces the viral load and reconstitutes immune function, but also decreases infection incidence rates by limiting viral transmission. The treatment algorithm in HIV has characteristically involved multiple drug regimens designed to tackle the virus on different levels. In the recent past, simplified dosing regimens through the emergence of single tablet regimens (STRs) or fixed dose combination (FDC) therapies have become increasingly popular amongst physicians and patients alike by increasing clinical efficacy thresholds and enabling patient compliance.

Atripla is a fixed-dose combination drug containing three active compounds, the two NRTIs Emtriva (emtricitabine/FTC) and Viread (tenofovir disoproxil fumarate/TDF) and BMS's NNRTI Sustiva (efavirenz/EFV). It can be used alone as a complete regimen or in combination with other antiretroviral agents. The mechanism of action of Atripla includes the following items (Atripla prescribing information, 2012).

FTC, a synthetic nucleoside analog of cytidine, inhibits the activity of HIV reverse transcriptase (RT) by competing with a natural substrate deoxycytidine 5'-triphosphate and by being incorporated into nascent viral DNA resulting in chain termination.

Tenofovir disoproxil fumarate (TDF), an acyclic nucleoside phosphonate diester analog of adenosine monophosphate, is converted into its active form (i.e., tenofovir diphosphate) by normal metabolic processes. Tenofovir diphosphate inhibits the activity of the HIV RT by competing with deoxyadenosine 5'-triphosphate (a natural substrate) and by terminating viral replication by incorporating into the viral DNA.

Efavirenz noncompetitively inhibits HIV RT by binding to a distinct location away from the active site of the enzyme.

Scope

- Overview of HIV, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Atripla including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Atripla for the top nine countries from 2012 to 2022.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan, Brazil and China

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for HIV
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Atripla performance
- Obtain sales forecast for Atripla from 2012-2022 in top nine countries (the US, France, Germany, Italy, Spain, the UK, Japan, Brazil and China)

Table of Contents

1 Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures 7
2 Introduction 8
2.1 Catalyst 8
2.2 Related Reports 8
3 Disease Overview 10
3.1 Etiology and Pathophysiology 10
3.1.1 Etiology 10
3.1.2 Pathophysiology 13
3.1.3 Prognosis 13
3.1.4 Quality of Life 14
3.2 Symptoms 14
3.2.1 Primary or Acute Infection 14
3.2.2 Chronic Infection 14
3.2.3 Advanced Infection/AIDS 15
4 Disease Management 16
4.1 Treatment Overview 16
5 Competitive Assessment 20
5.1 Overview 20
5.2 Strategic Competitor Assessment 20
6 Atripla (efavirenz/emtricitabine/tenofovir) 23
6.1 Overview 23
6.2 Efficacy 25
6.3 Safety 26
6.4 SWOT Analysis 26
6.5 Forecast 29
7 Appendix 30
7.1 Bibliography 30
7.2 Abbreviations 32
7.3 Methodology 34
7.4 Forecasting Methodology 34
7.4.1 HIV Prevalence 34
7.4.2 Percent Drug-Treated Patients 34
7.4.3 General Pricing Assumptions 35
7.4.4 Individual Drug Assumptions 36
7.4.5 Generic Erosion 36
7.5 Physicians and Specialists Included in this Study 37
7.5.1 Survery of Prescribing Physicians 38
7.6 About the Authors 39
7.6.1 Authors 39
7.6.2 Global Head of Healthcare 40
7.7 About GlobalData 41
7.8 Contact Us 41
7.9 Disclaimer 41

List of Tables

Table 1: Symptoms HIV 15
Table 2: Treatment Guidelines for HIV 17
Table 3: Most Prescribed Drugs for HIV by Class in the Global Markets, 2012 18
Table 4: Leading Treatments for HIV, 2012 22
Table 5: Product Profile – Atripla 24
Table 6: Atripla SWOT Analysis, 2012 28
Table 7: Global Sales Forecasts ($m) for Atripla, 2012-2022 29
Table 8: Physicians Surveyed, By Country 38

List of Figures

Figure 1: HIV Lifecycle 11

To order this report:
Pathology Industry: Atripla (HIV) - Forecast and Market Analysis to 2022

Contact Clare: [email protected]
US:(339) 368 6001
Intl:+1 339 368 6001

SOURCE Reportlinker